Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Timapiprant in Severe Eosinophilic Asthma (PERSEA)
NCT04049175Phase 3Terminated
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Aug 2019
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of timapiprant in eosinophilic asthma (EA), sponsored by Chiesi Farmaceutici S.p.A.. Started Aug 2019; status: terminated.
02
Drugs
timapiprant
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT04049175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04049175.